Curevac Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>CN</div>
CVAC -- USA Stock  

USD 94.49  4.24  4.29%

Today's article will go over Curevac NV. What exactly are Curevac NV shareholders getting in December? Curevac NV is currently traded for 86.00. The entity has historical hype elasticity of -0.47. The average price elasticity to hype of competition is about -0.2. The firm is forecasted to decline in value after the next press release, with the price expected to drop to 85.53. The average volatility of headline impact on the company stock price is huge, making predictions on the news or social media along less reliable. The price decrease on the next news is expected to be -0.55%, whereas the daily expected return is currently at 0.81 percent. Given the investment horizon of 30 days the next forecasted announcement will be in about 3 days.
Published over a month ago
View all stories for Curevac NV | View All Stories
Will Curevac NV continue to grow in December?
The firm's average rating is Buy from 2 analysts. Macroaxis provides advice on Curevac NV to complement and cross-verify current analyst consensus on Curevac NV. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.
The successful prediction of Curevac NV stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Curevac NV, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Curevac NV based on Curevac NV hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Curevac NV's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Curevac NV's related companies.

Use Technical Analysis to project Curevac expected Price

Curevac NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Curevac NV technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Curevac NV trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Curevac utilizes its cash?

To perform a cash flow analysis of Curevac NV, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Curevac NV is receiving and how much cash it distributes out in a given period. The Curevac NV cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Curevac NV Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (78.27 Million)

Another angle On Curevac NV

The current price rise of Curevac NV could raise concerns from investors as the firm it trading at a share price of 86.00 on 461,700 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in December. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.94. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Curevac NV partners.

Deferred Revenue Breakdown

Curevac NV Deferred Revenue is increasing over the years with slightly volatile fluctuation. Ongoing Deferred Revenue is projected to grow to about 80.3 M this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Curevac NV Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 73.52 Million
201070.36 Million
201973.52 Million
202080.35 Million

Our take on today Curevac NV rise

Current market risk adjusted performance is at 1.3. Curevac NV shows above-average downside volatility for the selected time horizon. We advise investors to inspect Curevac NV further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Curevac NV future alpha.

Our Bottom Line On Curevac NV

Whereas some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Curevac NV may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Curevac nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Curevac NV.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Curevac NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to